tiprankstipranks
Advertisement
Advertisement

RPRX Stock Latest News

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
The FlyRoyalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
3d ago
JNJ
RPRX
Zymeworks price target raised to $48 from $33 at Evercore ISI
PremiumThe Fly
Zymeworks price target raised to $48 from $33 at Evercore ISI
23d ago
RPRX
ZYME
Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
PremiumThe Fly
Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
1M ago
RPRX
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
PremiumThe Fly
Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
1M ago
ONC
JAZZ
Royalty Pharma price target raised to $50 from $45 at TD Cowen
PremiumThe Fly
Royalty Pharma price target raised to $50 from $45 at TD Cowen
1M ago
RPRX
The Week That Was, The Week Ahead: Macro and Markets, Feb. 15
PremiumMarket NewsThe Week That Was, The Week Ahead: Macro and Markets, Feb. 15
2M ago
J
W
Royalty Pharma Earnings Call Balances Strength And Risk
Premium
Company Announcements
Royalty Pharma Earnings Call Balances Strength And Risk
2M ago
RPRX
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs
Premium
The Fly
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs
2M ago
RPRX
Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
PremiumThe Fly
Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
2M ago
RPRX
Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B
PremiumThe Fly
Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B
2M ago
RPRX
Royalty Pharma reports Q4 portfolio receipts of $874M
PremiumThe Fly
Royalty Pharma reports Q4 portfolio receipts of $874M
2M ago
RPRX
Royalty Pharma PLC (RPRX) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Royalty Pharma PLC (RPRX) Q4 Earnings Cheat Sheet
2M ago
RPRX
Royalty Pharma upgraded to Buy from Neutral at UBS
PremiumThe FlyRoyalty Pharma upgraded to Buy from Neutral at UBS
2M ago
RPRX
Royalty Pharma price target raised to $50 from $48 at Citi
Premium
The Fly
Royalty Pharma price target raised to $50 from $48 at Citi
2M ago
RPRX
Royalty Pharma provides update on business performance
Premium
The Fly
Royalty Pharma provides update on business performance
3M ago
RPRX
Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
PremiumThe Fly
Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408
3M ago
RPRX
TEVA
Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
PremiumThe Fly
Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share
3M ago
RPRX
Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
PremiumThe Fly
Royalty Pharma acquires reaming royalty interest in Evrysdi for $240M upfront
3M ago
CHRO
RPRX
Royalty Pharma Announces Planned Legal Leadership Transition
PremiumCompany Announcements
Royalty Pharma Announces Planned Legal Leadership Transition
3M ago
8K
RPRX
Royalty Pharma Gains From FDA Approval of MYQORZO
PremiumCompany AnnouncementsRoyalty Pharma Gains From FDA Approval of MYQORZO
3M ago
8K
RPRX
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
Premium
The Fly
Royalty Pharma acquires royalty interest in Nuvalent’s neladalkib, zidesamtinib
4M ago
NUVL
RPRX
Royalty Pharma price target raised to $45 from $42 at TD Cowen
Premium
The Fly
Royalty Pharma price target raised to $45 from $42 at TD Cowen
4M ago
RPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >